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Deletion mutationGlucose-6-phosphate dehydrogenase (G6PD) deﬁciency, an X-linked disorder, is usually observed in
hemizygote males and very rarely in females. The G6PD class 1 variants, very uncommon, are associated with
chronic hemolytic anemia. Here we report a Portuguese woman who suffered in her sixties from a chronic
hemolytic anemia due to G6PD deﬁciency. Molecular studies revealed heterozygosity for an in-frame 18-bp
deletion, mapping to exon 10 leading to a deletion of 6 residues, 362–367 (LNERKA), which is a novel G6PD
class 1 variant, G6PD Tondela. Two of her three daughters, asymptomatic, with G6PD activity within the
normal range, are heterozygous for the same deletion. The patient's leukocyte and reticulocyte mRNA studies
revealed an almost exclusive expression of the mutant allele, explaining the chronic hemolytic anemia.
Patient whole blood genomic DNA HUMARA assay showed a balanced pattern of X chromosome inactivation
(XCI), but granulocyte DNA showed extensive skewing, harboring the mutated allele, implying that in whole
blood, lymphocyte DNA, with a very long lifetime, may cover up the current high XCI skewing. This
observation indicates that HUMARA assay in women should be assessed in granulocytes and not in total
leukocytes.tologia, Centro Hospitalar de
239 717216.
.L. Ribeiro).
l rights reserved.© 2011 Elsevier Inc. All rights reserved.Introduction
X chromosome inactivation (XCI) is an epigenetic process, unique
in mammals, by which one of the two X chromosomes in each cell is
inactivated in females early in embryogenesis [1]. Therefore, women
are a mosaic of paternal and maternal active X chromosome and a
theoretical 1:1 ratio of two cell lines with inactive maternal to
paternal X chromosome could be expected. The XCI ratio is usually
assessed analyzing protein variants directly in heterozygous females’
cells [2], transcribed mRNA expression [3] or DNA methylation status
of polymorphic X-linked genes, such as the human androgen receptor
(HUMARA) gene [4]. Deviation from the theoretical 1:1 ratio between
the 2 parental alleles is called skewing. Several reports using the
HUMARA assay show that the incidence of skewing is relatively low at
birth and in adult non-hematopoietic tissues, but higher and age-
dependent in hematopoietic cells, with 30–40% of healthy elderly
women reported to have skewing (greater than 75% expression of one
parental X chromosome) [5–12]. T lymphocytes show less evidence of
skewing with age than neutrophils, presumably reﬂecting the
neutrophils’ short half-life, whereas T lymphocytes are long-livingcells, and in consequence, some T cells are produced near the time of
study but others are derived from earlier stem cells [11–13]. This age-
related skewing in blood cells has been attributed to clonality as a
consequence of hematopoietic stem cell senescence [5,7,9].
Swierczek et al. report a discrepancy between the skewed XCI
observed in blood cells of 45 elderly women (ages 65–92 years; mean,
81.3 years) using the methylation-based HUMARA assay and a
transcriptional based assay: with HUMARA assay in granulocyte
DNA they found an age-dependent skewing at this locus, and
preferential methylation of one allele; using a quantitative polymer-
ase chain reaction (qPCR) transcriptional clonality assay to measure
allele-speciﬁc expression of 5 genes, subject to X-inactivation, they
did not ﬁnd clonal or oligoclonal hematopoiesis in 37 informative
healthy older women compared with younger women. The authors
concluded that skewed allelic methylation ratios in elderly women
observed by HUMARA assay are the result of an age-related
deregulated methylation of the HUMARA gene locus, but in the
absence of co-morbid conditions, healthy individuals do not exhibit
clonality or oligoclonality of hematopoiesis with aging [14]. Busque et
al. studied 100 women from elderly and young cohorts combined
(mean age, 64 years) using HUMARA and 2 independent transcription
clonality assays (one based on a quantitative allele-speciﬁc PCR and
the other based on TaqMan-SNP) and found similar skewing
incidences with the 3 different methods (40%±2%). The authors
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HUMARA assay document age-dependent skewing in females and
that skewing of XCI ratio seen in blood cells of aging women is a
genuine biologic phenomenon [6].
Until recently it has been assumed that the XCI skewing intensity
would be the same in all tissues. However, data from Bolduc et al.
shows that the skewing extent varies by tissue type, although
maintaining the direction (toward maternal or paternal allele) across
tissues, in accordance with the concept that the primary XCI occurs
during early development, prior to the splitting of the inner cell mass
and to tissue speciﬁcation [10].
In general, skewing may not have any biologic consequence;
however, extremely skewed XCI in blood cells has been reported
in severely affected females for a X-linked trait. Several cases of
symptomatic carrier females with speciﬁc X-linked genemutations, in
whom the X chromosome carrying the normal allele is predomi-
nantly inactivated, have been described in hemophilia A, [15]
hemophilia B, [16] sideroblastic anemia [17,18] and glucose 6-
phosphate dehydrogenase (G6PD) deﬁciency [19]. Moreover, studies
in Chinese women heterozygous for G6PD variants showed that
the frequency of G6PD deﬁciency increased with age, and that G6PD
activity was related to the degree of skewing of XCI determined by the
HUMARA assay [20].
G6PD catalyzes the ﬁrst step of the pentose phosphate pathway
and is the product of a housekeeping X-linked gene ubiquitous in its
expression in mammalian tissues [21]. More than 160 mutations have
been identiﬁed associated with G6PD deﬁciency, the great majority
consisting in single point mutations causing amino acids replace-
ments [22]. Few small in-frame nucleotide deletions have been
described, all in males, associated with chronic nonspherocytic
hemolytic anemia (CNSHA): 5 deletions of 1 amino acid, 1 deletion
of 2 amino acids and 1 deletion of 8 amino acids [22]. The remark that
nonsense, frameshifts or splicing mutations had not been found in
association with G6PD deﬁciency is probably due to the fact that the
hemizygous state for such null mutations, responsible for total
absence of G6PD activity, is incompatible with life. The exception is
the deletion of the invariant dinucleotide “ag” at the intron 10
acceptor splice-site, reported by Xu et al. which presumably causes a
deletion of 3, 9 or 20 amino acids due to the activation of cryptic
splicing sites in exon 11 [23].
In this work we illustrate the age-dependent skewing in a
Portuguese woman heterozygous for a novel G6PD class 1 variant,
who presented at the age of 74 years with chronic hemolytic anemia.
Differences in clinical manifestations between the patient and her two
daughterswith the same genotype are explained by the G6PDmutated
allele expression assessed by reverse transcription-polymerase chain
reaction (RT-PCR) method.
Materials and methods
Subjects
A74 year old Portuguesewoman presentedwith a history of chronic
hemolytic anemia with palpable spleen 5 cm below the left costalTable 1
Hematological and biochemical analysis summarised.
Patient Age
(years)
Hb (g/dL) n.r
12.0–16.0
MCV (ﬂ)
n.r. 80–96
Retics (%)
n.r. b2.0%
Leuk
(×109/L)
Neutr
(×109
Patient 74 9.4 114 28 9.81 4.69
Daughter1 37 12.3 96 3.7 8.15 4.80
Daughter2 36 11.9 94 2.8 6.6 4.49
Daughter3 35 12.1 92 0.8 6.8 4.30
Hb: hemoglobin (normal values: adult females, 120–160 g/L); MCV: mean cell volume (low
determined; n.r.: normal; Leuk: leukocytes (normal values: 4–10×109/L); Neutr: neutrophil
platelets (normal values: 150–400×109/L).margin, identiﬁed during the previous decade. The anemia was macro-
cytic with reticulocytosis: Hb=9.4 g/dL;MCV=114 fL; reticulocytes=
28%; unconjugated serum bilirubin 42 micromol/L (normal b17);
serum ferritin 400 ng/mL; G6PD activity in erythrocytes =16.6% of
normal. The patient had no history of anemia during her three full-term
pregnancies. The daughters (D1, D2, and D3), aged 37, 36 and 35 year
old, have normal hematological parameters and were also investigated
(Table 1).
Hematological studies and enzyme activity analysis
Blood was obtained by venipuncture and granulocyte and
lymphocyte fractions were isolated by Histopaque density gradient
as recommended by the manufacturer (Sigma-Aldrich). Hemato-
logical parameters were determined by standard methods [24].
G6PD enzyme activity assays in the red blood cells and leukocytes
lysates were performed by quantitative spectrophotometer analysis
according to the recommendations of the International Committee
for Standardization in Hematology (ICSH).
Electrophoresis of partial puriﬁed lysates was performed in
horizontal 20% starch gels, pH 7.6, and the G6PD mobility was
examined using a functional method (Harris and Hopkinson, 1976).
Molecular studies
Genomic DNA
After informed consent, genomic DNA was extracted from EDTA
peripheral blood (PB), and from granulocytes and lymphocytes
fractions using standard molecular protocols. The G6PD coding
exons 2–13 were ampliﬁed by polymerase chain reaction (PCR) and
tested for the common G6PD deﬁcient variants, as previously
described [25–27]. The amplicons were subjected to single strand
conformation polymorphism (SSCP) analysis and to direct sequencing
by dideoxy chain termination reaction, using the ABI Prism 310
genetic analyser (Applied Biosystems).
XIST gene
The Xist gene, involved in X chromosome inactivation, was tested
for the presence of the −43C→G mutation in the minimal promoter
region, using the restriction endonuclease HhaI [28].
RNA studies
Total RNA was isolated from top half of packed red blood cells
and leukocytes in PB by RNAeasy plus mini Kit (Qiagen) as per
manufacturer's recommendations. The isolated RNA was reverse
transcribed, primed with random hexamers, using First-Strand cDNA
synthesis kit (Amersham Biosciences) as described by the manufac-
turer. The cDNA was subjected to PCR using forward primer 5′-
acttttgcagccgtcgtc-3′ and reverse primer 5′-agaagacgtccaggatgagg-3′.
The resulting 331 bp amplicons, containing exons 9–11, were
electrophoresed through horizontal 10.0% bis-acrylamide gel. The
intensity of the reverse transcription-polymerase chain reaction (RT-
PCR) fragments was measured and integrated using the genescan
software “ImageMaster 1D Elite, version 2.01” (Hoefer Pharmacia/L)
Lymph
(×109/L)
Plat
(×109/L)
Total Bilirubin
(μmol/L) n.r b22
G6PD RBC
(% of N)
G6PD leukocytes
(% of N)
1.82 254 26.8 16.6 b10%
2.30 269 14.3 85.5 100
1.74 285 10.4 115.5 n.d.
2.05 271 8.8 100 n.d.
est normal values: adults, 80 fL); Retics: reticulocytes (normal values: 0–2%); n.d.: not
s (normal values: 2–7×109/L); Lymph: lymphocytes (normal values: 1–3×109/L); Plat:
290 L. Manco et al. / Blood Cells, Molecules, and Diseases 46 (2011) 288–293Biotech). The RT-PCR products were also subjected to Sanger's direct
sequencing using the ABI Prism 310 genetic analyzer (Applied
Biosystems).
HUMARA methylation assay
Genomic DNA isolated from blood total leukocytes, granulocytes
and lymphocytes fractions was subjected to the HUMARA methyla-
tion assay as previously reported [4]. Brieﬂy, genomic DNA was
treated overnight with and without the methylation-sensitive
endonuclease HhaI and subsequently subjected to PCR using primers
previously described ﬂanking the short tandem repeat (STR)
polymorphism in the HUMARA gene [12]. The PCR products were
analyzed using the automatic sequencer AlfExpress II (Amersham
Pharmacia Biotech). The allele's size and area under the curve (AUC)
was measured with the software ALFwin™ Fragment Analyser 1.00
(Amersham Pharmacia Biotech). The ratio of the active/inactive X
chromosomewas estimated according the equation deﬁned by Bolduc
et al. [10]:
Psup ¼ 1
A= Aþ að Þ
A′ = A′þa′ð Þ
A= Aþ að Þ
A′ = A′þa′ þ
a= Aþ a
a′ = A′þa′
0
BB@
1
CCA
A and A′ represent the AUC of the superior HUMARA allele from
digested and undigested sample, respectively; a and a′ represent the
AUC of the inferior HUMARA allele for the digested and undigested
sample, respectively. Psup indicates the percentage of cells expressing
the X chromosome bearing the superior allele. A Psup score equal
or greater than 75% or equal or less than 25% indicates skewing. The
Psup speciﬁes the direction of skewing: Psup N50% indicates the X
chromosome bearing the superior allele is predominant, while Psup
b50% indicates the opposite [10].
Results and discussion
We report a clinical case of a Portuguese woman referred to our
out-patient clinic at the age of 74 years with macrocytic chronic
hemolytic anemia due to G6PD deﬁciency. Her G6PD activity in red
blood cells was about 17% of normal and it was severely reduced
(b10% of the normal) in leukocytes. In spite of that, the patient has no
clinical evidence of decreased leukocyte functions, namely increased
susceptibility to bacterial or fungal infections, as it has been described
in patients with granulocytes G6PD activity below 5% of normal [29].
Her three daughters have erythrocytes G6PD activity within the
normal ranges (Table 1). The G6PD starch-gel electrophoresis
revealed only the normal migrating G6PD B band (data not shown).
Genomic DNA studies
Patient and daughters’ genomic DNAwas tested for G6PD A variant
(A376G) with FokI, conﬁrming the presence of the G6PD B alleles. The
amplicon containing exon 10 has a shift on SCCP gel electrophoresis,
implying the presence of a putative mutation, and the direct
sequencing was consistent with an 18-bp deletion at the heterozy-
gous state (data not shown). The 10.0% acrylamide gel electrophoresis
of the PCR fragment spanning exon 10 showed an abnormal fast
moving band, conﬁrming the patient to be heterozygous for the 18 bp
deletion (Fig. 1A). Two of her daughters (D1 and D2) were also
heterozygous for the 18 bp deletion; the third daughter (D3) was
homozygous for the wild type allele (Fig. 1A). The sequence analysis
of the promoter, whole coding exons and ﬂanking introns regions in
patient DNA excluded any additional mutations.
The −43C→G XIST promoter mutation, associated with nonran-
dom X chromosome inactivation [28], was not found in patient and
her daughters.mRNA studies
Patient reticulocytes and leukocytes G6PD mRNA expression
analysis spanning G6PD exons 9–11 showed markedly increased
expression of the mutant allele relative to the normal allele (N95% in
reticulocytes and ~80% higher in leukocytes), while daughter D1
mRNA exhibited similar expression of both mutated and normal
transcripts (~50% each in both leukocytes and reticulocytes) (Fig. 1B).
Probably due to different methods sensitivity, RT-PCR amplicon
G6PD exon 10 sequence analysis on patient's reticulocytes and
leukocytes failed to show the normal nucleotide sequence, reﬂecting
the markedly increased expression of the abnormal mRNA in both
hematopoietic cells. Moreover, the nucleotide sequencing proﬁle
conﬁrmed the presence of the 18-bp in-frame deletion (Fig. 1C) that is
predicted to remove 6 amino acids, p.362-p.367del (LNERKA). These 6
residues are located in the loop connecting β-strands J and K that form
part of the β-sheet that constitutes a scaffold for binding of the
structural NADP+, and extends across G6PD dimmer interface. Two
perfect 8-bp repeats (GCAAGGCC) mark the endpoints of the
pathogenic deletion, the 5′ breakpoint between nucleotides c.1076
and c.1083 and the 3′ breakpoint between nucleotides c.1094 and
c.1101 (Fig. 1C).
Therefore, mRNA studies support skewed XCI in the patient's
erythrocytes and leukocytes and a balanced XCI in daughter D1
leukocytes and erythrocytes, which is in accordance with their G6PD
activity and clinical phenotypes.
HUMARA assays
The pattern of X chromosome inactivation in patient genomic DNA
from whole blood (leukocytes), assessed by the methylation-based
HUMARA clonality assay (Fig. 2), showed a similar PCR ampliﬁcation
amount of two HUMARA alleles (278- and 287-bp) in accordance to a
balanced pattern of XCI (Fig. 2C-1), with a Psup score of 40%,
according to the equation reported by Bolduc et al. [10]. Thus, patient
HUMARA data was not in keeping with the blood G6PDmRNA studies
which point to a marked increase expression of the mutant allele,
accounting for the late development of her chronic hemolytic anemia.
To elucidate the discordance betweenmRNA and HUMARA studies
we performed lineage speciﬁc HUMARA analysis on DNA isolated
from granulocytes and lymphocytes fractions. In the granulocytes we
found a skewing of X-inactivation towards the 278-bp HUMARA allele
(Fig. 2C-2): Psup score of 16%, which means that the X chromosome
bearing the inferior HUMARA allele, associated to the G6PD mutated
allele, is predominantly expressed. In lymphocytes (Fig. 2C-2)
Psup=54% indicates no skewing, similar to the HUMARADNA studies
in the whole blood (Psup=40%), implying that the presence in whole
blood of a signiﬁcant number of T cells derived from earlier stem cells,
before the acquired skewing occurred, masked the high XCI skewing
in the granulocytes. These results are in accordance to previous
reports showing that skewing was markedly increased in older
women's granulocytes, but not in T cells [11–13]. As lymphocytes
have a long circulatory lifetime, these data are consistent with XCI
skewing developing with age, implying that HUMARA assay in whole
blood is not reliable to quantify the XCI skewing in older women.
The higher mRNA expression of the G6PDmutated allele in patient
leukocytes (~80%) is associated with the extreme X-skewed inacti-
vation in the granulocytes (Table 1). The presence of the long-lived
lymphocytes may explain the small normal band (~20% expression)
observed in RT-PCR analysis from leukocytes, corresponding to the
wild type G6PD allele, which is more intense than the faint normal
band obtained from reticulocytes cDNA (Fig. 1B).
The HUMARA pattern in whole blood DNA from daughter D1
showed an almost balanced XCI pattern between the maternal and
paternal allele: Psup=73%, indicating no skewing but a more active
father's 290-bp superior allele (Fig. 2C-1) in agreement with her
Fig. 1. (A) Electrophoretic analysis of genomic DNA PCR fragments from G6PD exon 10. Mother and daughters 1 and 2 showed the normal band and a faster moving band
corresponding to the G6PD allele containing the 18-bp deletion. (B) RT-PCR products from patient and daughter 1 reticulocytes and leukocytes spanning G6PD exons 9–11 showing
the normal band (331-bp) and the fast moving band (313-bp) corresponding to the abnormal allele preferential expressed in patient’ peripheral blood. (C) Patient leukocytes cDNA
sequence spanning the 18-bp deletion, within G6PD exon 10, showing the 8-bp repeat (GCAAGGCC) that marks the pathogenic deletion endpoints. M1, 1 kb marker (Invitrogen);
M2, marker (pBR322 digested with HinfI); P, patient; D1, daughter 1; D2, daughter 2; D3, daughter 3; C1 and C2, control samples.
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leukocytes and reticulocytes and with her normal hematological
parameters and G6PD activity.
Curiously, daughters D1 and D2, both heterozygous for the mutant
G6PD allele, present different mother's HUMARA alleles: 278- and
287-bp, respectively (Fig. 2B), implying a recombination event
between HUMARA and G6PD loci located far apart (about 86.8 Mb)
in the X chromosome. As D3 is homozygous for the G6PD wild type
allele and her X haplotype includes the 287-bp HUMARA allele, themost probable explanation is that the 278-bp androgen receptor
allele segregates with G6PD deﬁcient-allele, which means that
daughter D1 and D3 carry non-recombinants alleles and daughter
D2 the recombinant allele (as shown in Fig. 2A).
Thus, in a Portuguese woman with a chronic hemolytic anemia
exacerbation in her late sixties, we identiﬁed a new G6PD-deﬁcient
class I variant due to a 6 residues deletion near the enzyme dimmer
interface, in the context of the G6PD B haplotype (376A). We named
the new class 1 variant G6PD Tondela, after patient place of birth.
292 L. Manco et al. / Blood Cells, Molecules, and Diseases 46 (2011) 288–293The patient’ chronic hemolytic anemia is caused by an almost
exclusively expression of the mutant G6PD allele, as shown in
reticulocytes and leukocytes G6PD mRNA studies. HUMARA assaysFig. 2. (A) TheMendelian analysis of the HUMARA alleles showing alleles 278- and 287-
bp in patient’ DNA. The 3 daughters inherited the 290-bp allele from the father and,
from the mother daughter 1 inherited the 278-bp allele and daughters 2 and 3 the 287-
bp allele. (B) Patient's and relatives HUMARA alleles detected using the automatic
sequencer AlfExpress II (Amersham Pharmacia Biotech). (C) HUMARA methylation
assay in patient and daughter 1 performed in genomic DNA from peripheral whole
blood (1), lymphocytes and granulocytes (2). The arrow indicates the predominantly
active chromosome: as in the inactive X chromosome the HhaI site is methylated, no
digestion occurs and PCR ampliﬁcation takes place; in the active X chromosome, the
regular HhaI digestion leads to disruption of the HUMARA gene, preventing PCR
ampliﬁcation. P, patient; D1, daughter 1; D2, daughter 2; D3, daughter 3. Fig. 2 (continued).
293L. Manco et al. / Blood Cells, Molecules, and Diseases 46 (2011) 288–293showed an extensively skewed towards the chromosome harboring
the mutated allele in DNA from granulocytes, but not from
lymphocytes. Taken together, these data suggest a skewed X
chromosome inactivation process, which seems to aggravate with
age, as the deviation from the normal ratio was only observed in
granulocytes, with a short half-life.Acknowledgments
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